ALFA Finder| EBITDA Margin: guided vs achieved | 22.97% achieved Guided 22.00%–23.00%, -0.1% above the top of the range |
|---|
| Revenue growth | Consolidated ~14% YoY, mostly volume-led in Zerodol franchise. |
|---|---|
| Margins | Consolidated EBITDA 22.97% vs 21.68%; standalone 26.6% vs 25.46%. |
| Demand visibility | Chronic IPM ~17%; Ipca chronic ~20%, acute ~11%, at par. |
| Management confidence | Confident; reiterated FY27 guidance without revision or upgrade. |
Growth
Consolidated sales +14% YoY (₹2,557 to ₹2,910 Cr). Standalone exports +32%. Zerodol growth is about 8-9% volume and 4-4.5% price.
Outlook
Reiterated FY27 guidance: 14-16% revenue growth and 22-23% consolidated EBITDA margin, with no revision. Institutional sales may reach ₹325-340 Cr.
Risks
Freight, energy and input inflation persist. Unichem margin may stay at 11-13%. Pisgah remains loss-making. Institutional business may decline next year.
Last quarter's promises, checked
Delivered
- Domestic FY27 growth 12–13% → +14% (= BEAT)
- Institutional growth single-digit → +45% (= BEAT, lumpy)
Partly delivered
- Consolidated revenue growth 14–16% → ~14% (= PARTIAL, at floor)
- Consolidated EBITDA margin ~23% → 22.97% (= PARTIAL, just short)
- Year-end term debt ₹70 Cr → tracking ₹70–75 Cr (= PARTIAL, not yet due)
Missed
- Unichem EBITDA margin 13% → may stay 11–13% (= MISS)
Earnings Call Transcript filed with BSE, NSE: IPCALAB. Summary written with AI assistance from the document.
Ipca Laboratories Ltd: key numbers
- Share price
- ₹1,943.30
- Market cap
- ₹49,302 Cr
- Revenue (annual)
- ₹9,646 Cr
- Net profit (annual)
- ₹1,141 Cr
- P/E (TTM)
- 35.2×Sector 43.8×
- Promoter holding
- 44.72%+0.00% QoQ
- FII holding
- 11.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ipca Laboratories Ltd
All →Ipca Laboratories Q2 FY27 Results: Net Profit ₹389.3 Cr, Up 38.8% YoY
Ipca Laboratories Ltd reported revenue from operations of ₹2,910 Cr (+13.8% YoY) and net profit of ₹389.3 Cr (+38.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹389.3 Cr · +38.8% YoY
Ipca Laboratories Board Meeting Date
Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.
Ipca Laboratories Other Announcement
Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.
Ipca Laboratories Earnings Call Transcript: Key Takeaways
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
- Call
- Guides 16% growth
Ipca Laboratories Annual General Meeting
Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.
Ipca Laboratories Q1 FY27 Results: Net Profit ₹424.3 Cr, Up 82.2% YoY
Ipca Laboratories Ltd reported revenue from operations of ₹2,788 Cr (+20.8% YoY) and net profit of ₹424.3 Cr (+82.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹424.3 Cr · +82.2% YoY